SCHEMBL4646574

SCHEMBL4646574

CC(C)CCC#Cc1ccc(OCc2ccccc2)c(N2CC(=O)NS2(=O)=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.48
GRM2 Q14416 1/20 0.36
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
SNRNP200 O75643 1/20 0.34
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ACACB O00763 1/20 0.33
CHRNA7 P36544 2/20 0.32
PTPN2 P17706 2/20 0.32
PAX8 Q06710 1/20 0.32
MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4643548 0.85 PTPN1 (0.45) PTPN1SNRNP200HTR1ASLC6A2SLC6A4
SCHEMBL4646216 0.82 PTPN1 (0.49) PTPN1PDE4APDE4BPDE4CPDE4D
SCHEMBL4644890 0.81 PTPN1 (0.48) PTPN1GRM2SNRNP200PTPN2MMP1
SCHEMBL4643306 0.77 PTPN1 (0.53) PTPN1SLC6A4RAB9APTPN2
SCHEMBL4646906 0.77 PTPN1 (0.53) PTPN1PDE4APDE4BPDE4CPDE4D
SCHEMBL3929924 0.76 PTPN1 (0.45) PTPN1HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL3918479 0.75 PTPN1 (0.41) PTPN1PDE4APDE4BPDE4CPDE4D
SCHEMBL22412313 0.75 PTPN1 (0.46) PTPN1PTPN2
SCHEMBL6841900 0.74 PTPN1 (0.71) PTPN1PTPN2
Potassium SCHEMBL4647048 0.74 PTPN1 (0.50) PTPN1SNRNP200HTR1ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 PTPN1 10/4885GRM2 1323/4885PDE4A 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.